The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

Inclusion Criteria: * Aged at least eighteen years old. * Able to provide written informed consent. * Have a medical diagnosis of nickel allergy with at least a +2 reaction on the * ICDRG scoring system when challenged with nickel. * Fitzpatrick skin type 1-4. * Able to speak and understand Danish. Exclusion Criteria: * Received any topical immunomodulating or immunosuppresive treatment on the lower back two weeks prior, or applied crème/lotion on the lower back 24 hours prior to day 0. * Received systemic immunomodulating or immunosuppressive treatment four weeks prior to day 0. * Any skin lesions at the area of interest such as nevi, scar tissue or pigment changes. * Dermatitis and/or infection. * Recent (3 months or less) administration of a live virus vaccine. * Women of childbearing potential who are not taking adequate contraception or who are pregnant, plan to become pregnant during the study duration or lactating. * Taking part in any other intervention study. * Has any other condition which would, in the Investigator's opinion, deem the patient unsuitable for participation in the study (e.g. condition requiring long term or frequent oral steroid use). * Presence of any condition or use of any medication which precludes the use of the study drug. * Allergy to any of the ingredients in the drug.